Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Stable myopia control during 3-year wear of orthokeratology lenses in Danish children
Author Affiliations & Notes
  • Kamilla Bredsgaard Høeg
    Ophtalmology, Sygehus Lillebalt, Vejle, Syddanmark, Denmark
  • Flemming Møller
    Ophtalmology, Sygehus Lillebalt, Vejle, Syddanmark, Denmark
    Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, Odense, Syddanmark, Denmark
  • Trine Møldrup Jakobsen
    Ophtalmology, Sygehus Lillebalt, Vejle, Syddanmark, Denmark
    Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, Odense, Syddanmark, Denmark
  • Footnotes
    Commercial Relationships   Kamilla Bredsgaard Høeg None; Flemming Møller None; Trine Møldrup Jakobsen None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kamilla Bredsgaard Høeg, Flemming Møller, Trine Møldrup Jakobsen; Stable myopia control during 3-year wear of orthokeratology lenses in Danish children. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6623.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Few studies have investigated the effect of orthokeratology lenses (OKL) over a period of more than 2 years. The purpose of this study was to investigate if the efficacy of OKL decreases in Danish children during 3 years of usage measured by change in axial length (AL).

Methods : The CONTROL study was a 1:1 randomized controlled trial investigating the efficacy of OKL in Danish children aged 6-12 years during an 18-month follow-up. The intervention group used OKL, and the control group wore single-vision-spectacles. In the CONTROL2 study the same children were followed for additional 18 months with the control group crossed-over to OKL, and the OKL group continuing OKL. This sub-study presents the 3-year data from the original OKL group. The OKL used for this study was DreamLite® (CooperVision, San Ramon, California, USA). AL and central corneal thickness (CCT) on both eyes were measured with Lenstar LS900 (Haag-Streit, Koeniz, Switzerland) at 0, 6, 12, 18, 24, 30, and 36 months. Five to six measurements on both eyes were obtained at each follow-up visit. The change in AL was adjusted for the decrease in CCT caused by the OKL treatment. A nested mixed model was used to allow inclusion of data from both eyes and to include data from subjects who dropped out until dropout occurred. Stata/BE software (version 18.0; StataCorp, College Station, TX, USA) was used.

Results : The OKL group comprised 30 children (female 53%, age 9.77 years ± 1.38, cycloplegic spherical equivalent refractive error -2.25/-2.24 D ± 1.12/1.16, AL 24.12/24.11 mm ± 0.72/0.69 for right and left eye, respectively. During the 36-month follow-up 16 children dropped out leaving 14 children completing the study.
There was no statistically significant decline in treatment efficacy during the 3-year follow-up. The mean increase in AL from baseline to 6-month follow-up was 0.066 mm. Hereafter, the increase was 0.059 mm (mixed model, p = 0.89, 95% CI –0.11 to 0.09), 0.083 mm (p = 0.83, 95% CI –0.14 to 0.17), 0.082 mm (p = 0.88, 95% CI –0.19 to 0.23), 0.097 mm (p = 0.82, 95% CI –0.24 to 0.30), and 0.096 mm (p = 0.85, 95% CI –0.29 to 0.35) for 6 to 12, 12 to 18, 18 to 24, 24 to 30, and 30 to 36 months follow-up, respectively. However, there was an increasing trend.

Conclusions : The efficacy of OKL did not decrease significantly during 3 years of usage. However, the change in AL had an increasing trend.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×